Nemaura Includes Insulin on List of Drugs Eligible for EU DuoPack License Agreement
15 mars 2023 08h00 HE
|
Nemaura Medical, Inc
LOUGHBOROUGH, March 15, 2023 (GLOBE NEWSWIRE) -- Nemaura Medical, Inc. (NASDAQ: NMRD) (“Nemaura” or the “Company”), a medical technology company focused on developing and commercializing...
Nemaura Medical Announces Closing of Approximately $8.4 Million Registered Direct Offering and Concurrent Private Placement
31 janv. 2023 13h50 HE
|
Nemaura Medical, Inc
LOUGHBOROUGH, Jan. 31, 2023 (GLOBE NEWSWIRE) -- Nemaura Medical, Inc. (NASDAQ: NMRD) (“Nemaura” or the “Company”), a medical technology company focused on developing and commercializing non-invasive...
Nemaura Medical Announces Pricing of Approximately $8.4 Million Registered Direct Offering and Concurrent Private Placement
27 janv. 2023 08h20 HE
|
Nemaura Medical, Inc
LOUGHBOROUGH, Jan. 27, 2023 (GLOBE NEWSWIRE) -- Nemaura Medical, Inc. (NASDAQ: NMRD) (“Nemaura” or the “Company”), a medical technology company focused on developing and commercializing non-invasive...
Nemaura Medical to Present at the Bernstein 2ND Annual CGM Disruptors Conference
11 nov. 2022 08h00 HE
|
Nemaura Medical, Inc
Loughborough, England, Nov. 11, 2022 (GLOBE NEWSWIRE) -- Nemaura Medical, Inc. (NASDAQ: NMRD), a medical technology company focused on developing and commercializing noninvasive wearable diagnostic...
Nemaura Receives Provisional Purchase Order from Middle East Licensee TPMENA
12 oct. 2022 11h00 HE
|
Nemaura Medical, Inc
LOUGHBOROUGH, ENGLAND, Oct. 12, 2022 (GLOBE NEWSWIRE) -- Nemaura Medical, Inc. (NASDAQ: NMRD) (“Nemaura” or the “Company”), a medical technology company focused on developing and...
Nemaura Medical Strengthens Balance Sheet with Further Non-Dilutive Funding
23 mai 2022 06h30 HE
|
Nemaura Medical, Inc
Loughborough, England, May 23, 2022 (GLOBE NEWSWIRE) -- Nemaura Medical, Inc. (Nasdaq: NMRD), a medical technology company focused on commercializing a daily disposable wearable glucose sensor and...
MySugarWatch Continues Large-Scale Awareness Campaign Around Nemaura Medical’s sugarBEAT Non-Invasive Continuous Glucose Monitor Commencing Direct-to-Consumer Campaign in Daily Mail
17 mai 2022 08h00 HE
|
Nemaura Medical, Inc
Loughborough, England, May 17, 2022 (GLOBE NEWSWIRE) -- Nemaura Medical, Inc. (Nasdaq: NMRD), a medical technology company focused on developing and commercializing wearable diagnostic devices and...
MySugarWatch Launches Physician-Focused Ads in MIMS As Part of Large-Scale Awareness Campaign Around Nemaura Medical’s sugarBEAT Non-Invasive Continuous Glucose Monitor
03 mai 2022 08h00 HE
|
Nemaura Medical, Inc
Loughborough, England, May 03, 2022 (GLOBE NEWSWIRE) -- Nemaura Medical, Inc. (NASDAQ: NMRD), a medical technology company focused on developing and commercializing wearable diagnostic devices and...
Nemaura Medical Wins Innovation Awards
28 févr. 2022 08h00 HE
|
Nemaura Medical, Inc
Loughborough, England, Feb. 28, 2022 (GLOBE NEWSWIRE) -- Nemaura Medical, Inc. (Nasdaq: NMRD) (“Nemaura” or the “Company”), a medical technology company focused on developing and commercializing...
Nemaura Medical to Present at the H.C. Wainwright 23rd Annual Global Investment Virtual Conference
01 sept. 2021 08h00 HE
|
Nemaura Medical, Inc
Loughborough, England, Sept. 01, 2021 (GLOBE NEWSWIRE) -- Nemaura Medical, Inc. (NASDAQ: NMRD), a medical technology company focused on developing and commercializing non-invasive wearable...